Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

INDIANAPOLIS — Eli Lilly announced Wednesday the launch of higher doses of Zepbound — and that the company is lowering the price of certain doses. People taking Zepbound, or interested in starting, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...